Innosurge Biologics A/S — Credit Rating and Financial Key Figures
CVR number: 38768964
Alsikevej 16, 8920 Randers NV
Income statement (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 1 241.66 | - 695.49 | 992.73 | 2 183.24 | 2 077.81 |
| Employee benefit expenses | - 827.83 | -2 122.63 | -1 586.55 | -1 645.52 | -1 652.22 |
| Total depreciation | -0.41 | -4.96 | -4.96 | ||
| EBIT | 413.84 | -2 818.12 | - 594.23 | 532.77 | 420.63 |
| Other financial income | 18.15 | 74.76 | |||
| Other financial expenses | -19.10 | -68.06 | -21.53 | -61.23 | -88.57 |
| Pre-tax profit | 394.74 | -2 886.18 | - 615.76 | 489.69 | 406.82 |
| Income taxes | - 104.63 | 286.00 | 2.32 | ||
| Net earnings | 290.11 | -2 600.18 | - 613.44 | 489.69 | 406.82 |
Assets (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 34.31 | 29.35 | 24.39 | ||
| Tangible assets total | 34.31 | 29.35 | 24.39 | ||
| Investments total | |||||
| Non-curr. owed by group member comp. | 121.66 | ||||
| Long term receivables total | 121.66 | ||||
| Finished products/goods | 2 896.75 | 1 451.76 | 1 768.20 | 1 876.79 | 1 047.80 |
| Inventories total | 2 896.75 | 1 451.76 | 1 768.20 | 1 876.79 | 1 047.80 |
| Current trade debtors | 324.46 | 70.36 | 1 750.33 | 626.71 | 161.27 |
| Current amounts owed by group member comp. | 414.64 | 168.17 | 175.19 | 179.60 | |
| Prepayments and accrued income | 37.87 | 15.63 | 88.32 | 59.10 | |
| Current other receivables | 7.47 | 768.73 | 1 765.85 | ||
| Current deferred tax assets | 286.00 | ||||
| Short term receivables total | 739.11 | 401.70 | 1 934.13 | 1 658.95 | 2 165.81 |
| Cash and bank deposits | 647.86 | 1 112.66 | 69.01 | 1 082.31 | 1 458.20 |
| Cash and cash equivalents | 647.86 | 1 112.66 | 69.01 | 1 082.31 | 1 458.20 |
| Balance sheet total (assets) | 4 283.71 | 3 087.78 | 3 805.64 | 4 647.40 | 4 696.21 |
Equity and liabilities (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
| Retained earnings | 1 259.89 | 3 550.00 | 949.82 | 336.38 | 826.07 |
| Profit of the financial year | 290.11 | -2 600.18 | - 613.44 | 489.69 | 406.82 |
| Shareholders equity total | 2 050.00 | 1 449.82 | 836.38 | 1 326.07 | 1 732.89 |
| Non-current liabilities total | |||||
| Current loans from credit institutions | 4.79 | 29.70 | 63.03 | 45.63 | |
| Current trade creditors | 1 259.70 | 301.41 | 1 499.56 | 856.08 | 633.08 |
| Current owed to group member | 378.83 | 539.47 | 709.97 | 1 579.03 | 1 538.17 |
| Short-term deferred tax liabilities | 104.63 | ||||
| Other non-interest bearing current liabilities | 490.56 | 792.28 | 730.03 | 823.20 | 746.44 |
| Current liabilities total | 2 233.72 | 1 637.96 | 2 969.26 | 3 321.33 | 2 963.32 |
| Balance sheet total (liabilities) | 4 283.71 | 3 087.78 | 3 805.64 | 4 647.40 | 4 696.21 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.